These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32632231)

  • 1. Myosin activator improves cardiac function.
    Lim GB
    Nat Rev Cardiol; 2020 Sep; 17(9):540. PubMed ID: 32632231
    [No Abstract]   [Full Text] [Related]  

  • 2. Is myosin activation a new treatment for heart failure?
    Hasenfuss G
    Eur J Heart Fail; 2020 Sep; 22(9):1659-1661. PubMed ID: 32876374
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac Myosin Activators for the Treatment of Heart Failure: Stop Now or Push Ahead?
    Starling RC
    J Am Coll Cardiol; 2016 Mar; 67(12):1456-1458. PubMed ID: 27012406
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
    Manickam M; Jalani HB; Pillaiyar T; Sharma N; Boggu PR; Venkateswararao E; Lee YJ; Jeon ES; Jung SH
    Eur J Med Chem; 2017 Jul; 134():379-391. PubMed ID: 28432943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke.
    Rohde JA; Thomas DD; Muretta JM
    Proc Natl Acad Sci U S A; 2017 Mar; 114(10):E1796-E1804. PubMed ID: 28223517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac myosin and congestive heart failure in the dog.
    OLSON RE; ELLENBOGEN E; IYENGAR R
    Circulation; 1961 Aug; 24():471-82. PubMed ID: 13730904
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
    Manickam M; Pillaiyar T; Namasivayam V; Boggu PR; Sharma N; Jalani HB; Venkateswararao E; Lee YJ; Jeon ES; Son MJ; Woo SH; Jung SH
    Bioorg Med Chem; 2019 Sep; 27(18):4110-4123. PubMed ID: 31378598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel cardiac myosin activators for acute heart failure.
    Bragadeesh TK; Mathur G; Clark AL; Cleland JG
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1541-8. PubMed ID: 17922619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
    Psotka MA; Teerlink JR
    Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical characterization of cardiac myosin from normal dogs and from dogs with chronic congestive heart failure.
    DAVIS JO; CARROLL WR; TRAPASSO M; YANKOPOULOS NA
    J Clin Invest; 1960 Sep; 39(9):1463-71. PubMed ID: 13720201
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
    Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
    Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myosin, cardiac myosin light chain].
    Ishii J
    Nihon Rinsho; 2004 Nov; 62 Suppl 11():273-6. PubMed ID: 15628393
    [No Abstract]   [Full Text] [Related]  

  • 13. Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
    Manickam M; Jalani HB; Pillaiyar T; Boggu PR; Sharma N; Venkateswararao E; Lee YJ; Jeon ES; Son MJ; Woo SH; Jung SH
    Eur J Med Chem; 2018 Jan; 143():1869-1887. PubMed ID: 29224951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives of a myosin motor activator agent with increased selectivity.
    Nánási P; Komáromi I; Almássy J
    Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.
    Arimura T; Muchir A; Kuwahara M; Morimoto S; Ishikawa T; Du CK; Zhan DY; Nakao S; Machida N; Tanaka R; Yamane Y; Hayashi T; Kimura A
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1192-H1202. PubMed ID: 29451818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When fat meets the engine: implications of dietary rumenic acid on myosin-targeting therapies in heart failure.
    Sequeira V
    J Physiol; 2021 Aug; 599(15):3635-3636. PubMed ID: 34114231
    [No Abstract]   [Full Text] [Related]  

  • 17. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
    Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
    Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
    Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
    Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.
    Homburger JR; Green EM; Caleshu C; Sunitha MS; Taylor RE; Ruppel KM; Metpally RP; Colan SD; Michels M; Day SM; Olivotto I; Bustamante CD; Dewey FE; Ho CY; Spudich JA; Ashley EA
    Proc Natl Acad Sci U S A; 2016 Jun; 113(24):6701-6. PubMed ID: 27247418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Move quickly to detach: Strain rate-dependent myosin detachment and cardiac relaxation.
    Chung CS
    J Gen Physiol; 2020 Apr; 152(4):. PubMed ID: 32197272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.